Unique Biomarkers That May Clarify Treatment Of Triple-Negative Breast Cancer

Unique Biomarkers That May Clarify Treatment Of Triple-Negative Breast Cancer.
In an deed to rally the prognosis of patients battling triple-negative breast cancer, scientists have identified a single biomarker that may eventually allow some to receive a more targeted treatment. Although less uncommon, triple negative breast cancer is notoriously difficult to treat because receptor targeted therapies don't work.

The disease's big name refers to breast cancers that check-up negative for estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2(HER2), all of which exacerbate most breast cancer growth. "Triple-negative breast cancers currently shortage therapeutic targets and are managed with conventional chemotherapy," study author Dr Agnieszka K Witkiewicz, an friend professor of pathology at Thomas Jefferson University Hospital in Philadelphia, explained in a scuttlebutt release.